医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Accelsiors CRO Expands Global Footprint

2017年01月23日 PM10:30
このエントリーをはてなブックマークに追加


 

BUDAPEST, Hungary

Accelsiors today announced the opening of a new office in Gurgaon, India. This investment will provide our Biotechnology, Pharmaceutical and Medical Device Customers with greater access to patient populations in an increasingly well-regulated environment.

“Accelsiors is committed to providing our Customers with a depth of medical, scientific and regulatory expertise while conducting clinical studies with utmost quality,” said Mihaly Juhasz, MD, Accelsiors’ CEO. “Our 20 years of experience in the biosimilar sector and ability to provide stand-alone services (biometrics) has driven us to make this important investment.”

The Asian biosimilar development market is growing at a rapid pace and Accelsiors is now positioned to provide an even greater level of support to current and prospective Customers. Additionally, the added headcount enables us to provide a quality-driven, scalable solution to functional service provision, specifically biometrics.

“We are honored to be a part of Accelsiors global expansion,” said Shabbir Rangwala, Vice President, Operations. “Not only will Accelsiors be creating new jobs in India, but the expansion represents a renewed level of confidence in the quality of service delivery in the region.”

As the leader of the Asian Operations Team, Mr. Rangwala will oversee local operations while establishing and executing strategic growth strategies across the region.

About Accelsiors

Accelsiors is a scientifically-driven CRO committed to serving the needs of its Sponsors with the highest level of quality. We provide a full array of services and pride ourselves on having ready access to treatment naive patient populations. From consulting with you on the optimal design of your protocol to providing a final CSR, and all services in between; we are here to help.

We possess a depth of medical and scientific expertise which provides us with the knowledge necessary to be a value-added partner for Sponsors working in challenging disease indications. This expertise, coupled with highly educated, hard-working and principled staff, makes for a great combination. We are where the patients are and know the Investigators necessary to assist our Sponsors in achieving their enrollment objectives. Accelsiors is currently conducting studies in over 30 countries utilizing a combination of office-based and regional-based employees.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170123005055/en/

CONTACT

Accelsiors
Ty Quinn, +1 843-714-9210
Executive Vice President,
Global Commercial Operations
t.quinn@accelsiors.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease